Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
43 hedge funds and large institutions have $21.3M invested in Hepion Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 6 closing their positions.
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
46% more capital invested
Capital invested by funds: $14.6M → $21.3M (+$6.7M)
13% more funds holding
Funds holding: 38 → 43 (+5)
3% more call options, than puts
Call options by funds: $1.42M | Put options by funds: $1.38M
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.5M |
| 2 |
Two Sigma Advisers
New York
|
+$1.37M |
| 3 |
ACM
Altium Capital Management
New York
|
+$816K |
| 4 |
State Street
Boston,
Massachusetts
|
+$591K |
| 5 |
Two Sigma Investments
New York
|
+$448K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$560K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$296K |
| 3 |
Renaissance Technologies
New York
|
-$290K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$225K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$212K |
HEPA Hedge Fund Activity: Q2 2021 in Review
43 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q2 2021, worth a combined $21.3M — up 46% from $14.6M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new HEPA positions and 6 closed out — a net gain of 5 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $2.5M. The largest seller was Sabby Management, exiting entirely with an estimated $560K sold.
- 43 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q2 2021, up from 38 in Q1 2021.
- Funds reported $21.3M of Hepion Pharmaceuticals stock for Q2 2021, up 46% quarter-over-quarter.
- 11 funds opened new Hepion Pharmaceuticals positions in Q2 2021 and 6 closed out, a net change of +5 holders.
- The largest Hepion Pharmaceuticals buyer in Q2 2021 was Ikarian Capital, an estimated $2.5M added.
- The largest Hepion Pharmaceuticals seller in Q2 2021 was Sabby Management, an estimated $560K sold.
Based on aggregated 13F filings for Q2 2021.